Skip to main content
GutCited

Bifidobacterium breve for Irritable Bowel Syndrome (IBS)

D Early Research Only preliminary research exists (lab studies, case reports).

Limited data from small studies. Preliminary evidence for symptom improvement.

D

The Bottom Line

Limited data from small studies. Preliminary evidence for symptom improvement.

Key Study Findings

Randomized Controlled Trial 4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g vs: Placebo Outcome: Constipation symptoms P = 0.005

Population: IBS patients

Controlled Clinical Trial
Gut Microbiome Alterations Following Oral Serum-Derived Bovine Immunoglobulin Administration in the Management of Dysbiosis.
Dose: Serum-derived bovine immunoglobulin (SBI) vs: Pre-treatment baseline Outcome: Gut microbiome changes

Population: IBD and IBS patients

animal_study
Dose-Response Efficacy and Mechanisms of Orally Administered Bifidobacterium breve CCFM683 on IMQ-Induced Psoriasis in Mice.
Dose: 10^8, 10^9, or 10^10 CFU/day Bifidobacterium breve CCFM683 vs: Placebo Effect: substantial decrease in keratin 16, 17 and involucrin at 10^9 and 10^10 CFU/day; dose-response thres not_reported
Randomized Controlled Trial 24 weeks Double-blind
Clinical studies on alleviating the symptoms of irritable bowel syndrome.
Dose: Probiotic combination (LGG + 3 strains) daily vs: Placebo Outcome: IBS total symptom score reduction Effect: 42% reduction vs 6% placebo

Population: IBS patients

Randomized Controlled Trial n=103 24 weeks Double-blind
A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.
Dose: Probiotic capsule daily (LGG, LC705, Bb99, JS) vs: Placebo capsule Outcome: IBS total symptom score Effect: -7.7 points (95% CI: -13.9 to -1.6); 42% vs 6% 0.015

Population: IBS patients meeting Rome I or II criteria

Randomized Controlled Trial n=70 4 weeks Double-blind
Probiotics in the treatment of irritable bowel syndrome.
Dose: L. plantarum LP01 + B. breve BR03 or L. acidophilus LA02 vs: Placebo (starch) Outcome: Pain score and IBS severity score Effect: Pain: 42-49% vs 25% decrease (p<0.05); severity: 49-56% vs 8% <0.001

Population: IBS patients (Rome II criteria)

Key Statistics

2

Studies

150

Participants

↑

Positive

D

Grade

Referenced Papers

Archivos argentinos de … 2024 3 citations
Journal of clinical … 2004 205 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

General:
1-10 billion CFU/day
Adult Gi Support:
5-10 billion CFU/day
Neonatal Support:
1-5 billion CFU/day (as directed by pediatrician)

Upper limit: Well-tolerated up to 10 billion CFU/day in clinical trials

Dosages Studied in Research

Dosage Duration Effect N
2 g 4 weeks Mixed --
Serum-derived bovine immunoglobulin (SBI) -- Positive --
10^8, 10^9, or 10^10 CFU/day Bifidobacterium breve CCFM683 -- Positive --
Probiotic combination (LGG + 3 strains) daily 24 weeks Positive --
Probiotic capsule daily (LGG, LC705, Bb99, JS) 24 weeks Positive 103
L. plantarum LP01 + B. breve BR03 or L. acidophilus LA02 4 weeks Positive 70
VSL-3 probiotic preparation 3 weeks Positive 10

Best taken: Before meals or on empty stomach; for infants, mix with breast milk or formula

Safety & Side Effects

Reported Side Effects

  • ⚠ Mild gas during initial use
  • ⚠ Occasional loose stools in infants (transient)
  • ⚠ Rare abdominal discomfort
  • ⚠ Very rare: bacteremia in immunocompromised individuals

Known Interactions

  • ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • ● Immunosuppressants (use with caution in immunocompromised patients)

Tolerable upper intake: Well-tolerated up to 10 billion CFU/day in clinical trials

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium breve?
Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

References

  1. [1] Fabiana Bocchio et al.. Microbiome Res Rep. 2025. Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases. doi:10.20517/mrr.2024.52 PubMed
  2. [2] L Drago et al.. Benef Microbes. 2025. A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults. doi:10.1163/18762891-bja00097 PubMed
  3. [3] Ida Marie Bruun Grønbæk et al.. Front Nutr. 2025. Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results … doi:10.3389/fnut.2025.1701341 PubMed
  4. [4] Mattia Tinazzi et al.. Yale J Biol Med. 2024. Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro … doi:10.59249/JOMF5336 PubMed
  5. [5] Young Hoon Chang et al.. J Neurogastroenterol Motil. 2024. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. doi:10.5056/jnm23036 PubMed
  6. [6] María Del C Toca et al.. Arch Argent Pediatr. 2024. Postbiotics: A new member in the biotics family. doi:10.5546/aap.2023-10168.eng PubMed
  7. [7] Sabine Hazan et al.. Cureus. 2024. Gut Microbiome Alterations Following Oral Serum-Derived Bovine Immunoglobulin Administration in the Management of Dysbiosis. doi:10.7759/cureus.75884 PubMed
  8. [8] Han Chen et al.. J Transl Med. 2023. Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data. doi:10.1186/s12967-023-03953-7 PubMed
  9. [9] Xinqi Chen et al.. Nutrients. 2023. Dose-Response Efficacy and Mechanisms of Orally Administered Bifidobacterium breve CCFM683 on IMQ-Induced Psoriasis in Mice. doi:10.3390/nu15081952 PubMed
  10. [10] Seung Yong Shin et al.. J Neurogastroenterol Motil. 2022. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … doi:10.5056/jnm21202 PubMed
  11. [11] Yae Jin Choi et al.. J Microbiol Biotechnol. 2022. Immunomodulatory Effects of Bifidobacterium spp. and Use of Bifidobacterium breve and Bifidobacterium longum on Acute Diarrhea in Children. doi:10.4014/jmb.2206.06023 PubMed
  12. [12] Edgar Torres-Maravilla et al.. Sci Rep. 2022. Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome. doi:10.1038/s41598-022-21746-8 PubMed
  13. [13] Carrie A M Wegh et al.. J Clin Gastroenterol. 2018. Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. doi:10.1097/MCG.0000000000001054 PubMed
  14. [14] Hyuk Yoon et al.. J Clin Biochem Nutr. 2015. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a … doi:10.3164/jcbn.15-14 PubMed
  15. [15] María Ortiz-Lucas et al.. Rev Esp Enferm Dig. 2013. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. doi:10.4321/s1130-01082013000100005 PubMed
  16. [16] Bong Ki Cha et al.. J Clin Gastroenterol. 2012. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … doi:10.1097/MCG.0b013e31823712b1 PubMed
  17. [17] Eoin Barrett et al.. PLoS One. 2012. Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel … doi:10.1371/journal.pone.0048159 PubMed
  18. [18] E O'Sullivan et al.. Benef Microbes. 2011. BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels? doi:10.3920/BM2011.0015 PubMed
  19. [19] D P McKernan et al.. Neurogastroenterol Motil. 2010. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. doi:10.1111/j.1365-2982.2010.01520.x PubMed
  20. [20] Anna Lyra et al.. BMC Gastroenterol. 2010. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. doi:10.1186/1471-230X-10-110 PubMed
  21. [21] K Kajander et al.. Aliment Pharmacol Ther. 2007. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. doi:10.1111/j.1365-2036.2007.03391.x PubMed
  22. [22] Kajsa Kajander et al.. Asia Pac J Clin Nutr. 2006. Clinical studies on alleviating the symptoms of irritable bowel syndrome. PubMed
  23. [23] K Kajander et al.. Aliment Pharmacol Ther. 2005. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. doi:10.1111/j.1365-2036.2005.02579.x PubMed
  24. [24] Alfredo Saggioro. J Clin Gastroenterol. 2004. Probiotics in the treatment of irritable bowel syndrome. doi:10.1097/01.mcg.0000129271.98814.e2 PubMed
  25. [25] P Brigidi et al.. Res Microbiol. 2001. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome … doi:10.1016/s0923-2508(01)01254-2 PubMed

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.